Cargando…
Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib
Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and activator of transcription proteins pathway. Ruxolitin...
Autores principales: | Hanna, Ramy M., Khalid, Maham, El-Nour, Lama Abd, Selamet, Umut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784127/ https://www.ncbi.nlm.nih.gov/pubmed/31527456 http://dx.doi.org/10.3390/antibiotics8030150 |
Ejemplares similares
-
Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016) -
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab
por: Hanna, Ramy M, et al.
Publicado: (2020) -
Acute interstitial nephritis and drug-induced systemic lupus
erythematosus due to chlorthalidone and amiodarone: A case
report
por: Selamet, Umut, et al.
Publicado: (2020) -
Urinary tract infection with Klebsiella pneumoniae in Patients with Chronic Kidney Disease
por: CRISTEA, OANA MARIANA, et al.
Publicado: (2017) -
Combination Therapy for Multidrug-Resistant Klebsiella Pneumoniae Urinary Tract Infection
por: Yasin, Faizan, et al.
Publicado: (2017)